Our Science
OUR SCIENCE
Congress Presentations
This section includes posters and presentations related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets presented at scientific congresses in the past three years.
ESMO 2023 | Madrid, Spain
Oct 20 - 24, 2023
Poster
Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Estrogen Receptor+/Human Epidermal Growth Factor Receptor 2-Advanced Breast Cancer: Update of Dose Escalation Results From a Phase 1/2 TrialESMO 2023 | Madrid, Spain
Oct 20 - 24, 2023
Poster
Phase 1/2 Study of Bavdegalutamide, a PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer: Radiographic Progression-Free Survival in Patients With Androgen Receptor Ligand-Binding Domain MutationISSX 2023 | Boston, MA
Sep 10 - 13, 2023
Poster
In Vitro Evaluation of PROTAC® Androgen Receptor Degrader ARV-766 for Cytochrome P450- and Transporter-Mediated Drug-Drug InteractionACCP 2023 | Bellevue, WA
Sep 10 - 12, 2023
Poster
Drug-Drug Interaction Study of the PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader Bavdegalutamide in Combination With the CYP3A4 Inhibitor Itraconazole in Healthy VolunteersACCP 2023 | Bellevue, WA
Sep 10 - 12, 2023
Poster
The Effect of Food and the Proton Pump Inhibitor Esomeprazole on the Single-Dose Pharmacokinetics and Safety of the PROteolysis Targeting Chimera (PROTAC) Androgen Receptor Degrader Bavdegalutamide in Healthy VolunteersACCP 2023 | Bellevue, WA
Sep 10 - 12, 2023
Poster
The Effect of Food and the Proton Pump Inhibitor Esomeprazole on the Single-Dose Pharmacokinetics and Safety of ARV-766, a PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader, in Healthy VolunteersMDS 2023 | Copenhagen, Denmark
Aug 27 - 31, 2023
Poster
Development of Potent, Orally Bioavailable, and Highly Selective LRRK2 PROTAC® Degrader Molecules as Potential Disease Modifying Therapeutics for Parkinson’s DiseaseMDS 2023 | Copenhagen, Denmark
Aug 27 - 31, 2023
Poster
LRRK2 PROTAC® Degrader Molecules Induce Robust Biomarker Responses in Preclinical In Vivo Pharmacology Studies Following Acute and Chronic Oral DosingASCO 2023 | Chicago, IL
Jun 2 - 6, 2023